Briquilimab  (Synonyms: JSP-191)

Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric; Humanized

CD117 (c-Kit)^[1]

2574591-89-0

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded CD117/c-kit Protein, Human (HEK293, His, HY-P72752) on AHC2 biosensor, can bind Briquilimab with an affinity constant of 5.634E-09 M as determined in BLI assay.
• 
  Immobilized Human c-Kit Protein (ECD, His Tag) can bind Briquilimab. The EC₅₀ for this effect is 1.72 ng/mL.

• [1]. Agarwal R, et al. First report of non-genotoxic conditioning with JSP191 (anti-CD117) and hematopoietic stem cell transplantation in a newly diagnosed patient with severe combined immune deficiency[J]. Blood, 2020, 136: 10.